{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:13:00Z","timestamp":1793463180306,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016348","name":"Shenzhen Virtual University Park","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejmech.2024.116579","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:16:19Z","timestamp":1718306179000},"page":"116579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules"],"prefix":"10.1016","volume":"275","author":[{"given":"Zhichao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiandong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7812-7238","authenticated-orcid":false,"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5705-6377","authenticated-orcid":false,"given":"Shengtao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1961-0402","authenticated-orcid":false,"given":"Jinyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116579_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116579_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2004.05.018","article-title":"Protein tyrosine phosphatases in the human genome","volume":"117","author":"Alonso","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116579_bib3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/dvdy.449","article-title":"The role of the protein tyrosine phosphatase SHP2 in ossification","volume":"251","author":"Zhang","year":"2022","journal-title":"Dev. Dynam."},{"key":"10.1016\/j.ejmech.2024.116579_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1110\/ps.062128706","article-title":"The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1","volume":"15","author":"Eswaran","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2024.116579_bib5","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1074\/jbc.270.7.2897","article-title":"Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains","volume":"270","author":"Pluskey","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0969-2126(98)00027-6","article-title":"Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2","volume":"6","author":"Barford","year":"1998","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2024.116579_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.celrep.2015.09.019","article-title":"Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia","volume":"13","author":"Mulero-Navarro","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116579_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116579_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem"},{"key":"10.1016\/j.ejmech.2024.116579_bib10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116579_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20061548","article-title":"Protein tyrosine phosphatase function: the substrate perspective","volume":"402","author":"Tiganis","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2024.116579_bib12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural killer cell signaling pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116579_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116579_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.cr.7290055","article-title":"The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions","volume":"10","author":"Qu","year":"2000","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2016.07.010","article-title":"Sticking it to cancer with molecular glue for SHP2","volume":"30","author":"Ran","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2024.116579_bib16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cellsig.2005.05.016","article-title":"A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail","volume":"17","author":"Poole","year":"2005","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2024.116579_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2024.116579_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116579_bib19","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112117","article-title":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","volume":"190","author":"Shen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4155\/fmc.14.88","article-title":"Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention","volume":"6","author":"Butterworth","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2024.116579_bib23","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116579_bib24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2014.12.052","article-title":"Words of wisdom. Re: safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"67","author":"Daskivich","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2024.116579_bib25","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116579_bib26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib27","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2174\/138161210791209027","article-title":"Targeting protein tyrosine phosphatases for anticancer drug discovery","volume":"16","author":"Scott","year":"2010","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2024.116579_bib28","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1016\/j.bmc.2015.03.027","article-title":"Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases","volume":"23","author":"Chio","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1021\/bi5013595","article-title":"Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2","volume":"54","author":"Chio","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2024.116579_bib30","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.1c02008","article-title":"Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","article-title":"SHP2 sails from physiology to pathology","volume":"58","author":"Tajan","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ejmech.2024.116579_bib32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/med.21890","article-title":"Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery","volume":"42","author":"Song","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116579_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6807-14-10","article-title":"Structural insights into Noonan\/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)","volume":"14","author":"Qiu","year":"2014","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.ejmech.2024.116579_bib34","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1016\/j.bmc.2017.10.025","article-title":"Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2","volume":"25","author":"LaRochelle","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib35","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib36","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib37","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acs.jmedchem.8b01725","article-title":"Optimization of fused bicyclic allosteric SHP2 inhibitors","volume":"62","author":"Bagdanoff","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib38","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/acs.jmedchem.8b01726","article-title":"6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors","volume":"62","author":"Sarver","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib39","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib40","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116579_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103875","article-title":"Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors","volume":"100","author":"Liu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115585","article-title":"Design, synthesis, activity and molecular dynamics studies of 1,3,4-thiadiazole derivatives as selective allosteric inhibitors of SHP2 for the treatment of cancer","volume":"258","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/acsmedchemlett.3c00059","article-title":"Discovery of a novel series of potent SHP2 allosteric inhibitors","volume":"14","author":"Petrocchi","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116579_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/14756366.2022.2151594","article-title":"Discovery of the SHP2 allosteric inhibitor 2-((3R,4R)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-(2,3-dichlorophenyl)-3-methylpyrrolo[2,1-f][1,2,4] triazin-4(3H)-one","volume":"38","author":"Luo","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114106","article-title":"Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors","volume":"230","author":"Tang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib46","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1021\/acs.jmedchem.7b01520","article-title":"Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment","volume":"60","author":"Xie","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115305","article-title":"Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment","volume":"253","author":"Luo","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115019","article-title":"PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer","volume":"398","author":"Chen","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116579_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acsmedchemlett.2c00454","article-title":"Discovery of a novel series of imidazopyrazine derivatives as potent SHP2 allosteric inhibitors","volume":"14","author":"Torrente","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116579_bib50","doi-asserted-by":"crossref","first-page":"15141","DOI":"10.1021\/acs.jmedchem.1c01132","article-title":"Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a potent and orally bioavailable SHP2 inhibitor","volume":"64","author":"Czako","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib51","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","article-title":"Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib52","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1021\/acs.jmedchem.3c00992","article-title":"Identification of a novel, potent, and orally bioavailable guanidine-based SHP2 allosteric inhibitor from virtual screening and rational structural optimization for the treatment of KRAS mutant cancers","volume":"66","author":"Hou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/acs.jmedchem.8b00513","article-title":"Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib54","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1021\/acs.jmedchem.3c02118","article-title":"Fragment-based discovery of allosteric inhibitors of SH2 domain-containing protein tyrosine phosphatase-2 (SHP2)","volume":"67","author":"Day","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2024.03.028","article-title":"Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor","author":"Tang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116579_bib56","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd.2018.201","article-title":"Phosphatases start shedding their stigma of undruggability","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116579_bib57","doi-asserted-by":"crossref","first-page":"15973","DOI":"10.1021\/acs.jmedchem.1c01371","article-title":"Targeting oncogenic src homology 2 domain-containing phosphatase 2 (SHP2) by inhibiting its Protein\u2013Protein interactions","volume":"64","author":"Bobone","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib58","unstructured":"Dose finding study of TNO155 in adult patients with advanced solid tumors. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03114319."},{"key":"10.1016\/j.ejmech.2024.116579_bib59","unstructured":"A first-in-human study of JAB-3068 (SHP2 inhibitor) in adult patients with advanced solid tumors in China. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03565003."},{"key":"10.1016\/j.ejmech.2024.116579_bib60","unstructured":"A first-in-human, phase 1 study of JAB-3312 in adult patients with advanced solid tumors. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04045496."},{"key":"10.1016\/j.ejmech.2024.116579_bib61","unstructured":"Dose escalation of RMC-4630 monotherapy in relapsed\/refractory solid tumors. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03634982."},{"key":"10.1016\/j.ejmech.2024.116579_bib62","unstructured":"RLY-1971 in subjects with advanced or metastatic solid tumors. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04252339."},{"key":"10.1016\/j.ejmech.2024.116579_bib63","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib64","unstructured":"First-in-human study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04528836."},{"key":"10.1016\/j.ejmech.2024.116579_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3005","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","volume":"39","author":"Brana","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116579_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116579_bib67","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 Inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116579_bib68","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.celrep.2016.11.048","article-title":"Dual Shp2 and Pten deficiencies promote non-alcoholic steatohepatitis and genesis of liver tumor-initiating cells","volume":"17","author":"Luo","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116579_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109974","article-title":"Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment","volume":"37","author":"Chen","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116579_bib70","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.32555","article-title":"Pharmaceutical SH2 domain\u2013containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity","volume":"77","author":"Liu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116579_bib71","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1038\/s41467-021-26697-8","article-title":"Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib72","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib73","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116579_bib74","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116579_bib75","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib76","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104788","article-title":"Novel PROTACs for degradation of SHP2 protein","volume":"110","author":"Zheng","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib79","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.biochem.1c00377","article-title":"Targeted degradation of the oncogenic phosphatase SHP2","volume":"60","author":"Vemulapalli","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2024.116579_bib80","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 inhibition sensitizes diverse oncogene-addicted solid tumors to re-treatment with targeted therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116579_bib81","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib82","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116579_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116579_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116579_bib85","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2174\/1568009614666140717105001","article-title":"Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis","volume":"14","author":"Huang","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2024.116579_bib86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41590-022-01385-x","article-title":"SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses","volume":"24","author":"Christofides","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2024.116579_bib87","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib88","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/2326-6066.CIR-19-0744","article-title":"SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small cell lung cancer","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib89","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib90","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116579_bib91","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1535-7163.MCT-19-0170","article-title":"Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers","volume":"18","author":"Hao","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116579_bib92","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.annonc.2023.09.1839","article-title":"653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors","volume":"34","author":"Wang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2024.116579_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116579_bib94","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-18-0915","article-title":"Shipping out MEK inhibitor resistance with SHP2 inhibitors","volume":"8","author":"Torres-Ayuso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116579_bib95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","article-title":"SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116579_bib96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.30989","article-title":"Overriding adaptive resistance to Sorafenib through combination therapy with src homology 2 domain-containing phosphatase 2 blockade in hepatocellular carcinoma","volume":"72","author":"Leung","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116579_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10420","article-title":"The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc 42","volume":"7","author":"Tien","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib98","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.4497","article-title":"SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors","volume":"24","author":"Dardaei","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib99","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acschembio.7b00980","article-title":"Dual allosteric inhibition of SHP2 phosphatase","volume":"13","author":"Fodor","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116579_bib100","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116579_bib101","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib102","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib103","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116579_bib104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/cells8040321","article-title":"Updates on the CDK4\/6 inhibitory strategy and combinations in breast cancer","volume":"8","author":"Sobhani","year":"2019","journal-title":"Cells-Basel"},{"key":"10.1016\/j.ejmech.2024.116579_bib105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116579_bib106","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116579_bib107","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-18-0410","article-title":"MAPK reliance via acquired CDK4\/6 inhibitor resistance in cancer","volume":"24","author":"de Leeuw","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib108","unstructured":"Novartis Pharmaceuticals. Phase Ib study of TNO155 in combination with spartalizumab or ribociclib in selected malignancies. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04000529."},{"key":"10.1016\/j.ejmech.2024.116579_bib109","series-title":"Compounds and Compositions for Inhibiting the Activity of SHP2. WO 2016203406 A1","author":"Chen","year":"2016"},{"key":"10.1016\/j.ejmech.2024.116579_bib110","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1073\/pnas.0809645106","article-title":"Crystal structure of human CDK4 in complex with a D-type cyclin","volume":"106","author":"Day","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116579_bib111","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116579_bib112","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/acs.jmedchem.8b00209","article-title":"Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a novel inhibitor targeting cyclin-dependent kinase 4\/9 (CDK4\/9) and histone deacetlyase1 (HDAC1) against malignant cancer","volume":"61","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.07.044","article-title":"Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis","volume":"181","author":"Huang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib114","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1021\/acs.jmedchem.2c00063","article-title":"Discovery of a novel src homology-2 domain containing protein tyrosine Phosphatase-2 (SHP2) and cyclin-dependent kinase 4 (CDK4) dual inhibitor for the treatment of triple-negative breast cancer","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib115","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1021\/acs.jmedchem.1c00413","article-title":"Efficient synthesis and bioevaluation of novel dual Tubulin\/Histone deacetylase 3 Inhibitors as potential anticancer agents","volume":"64","author":"Peng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib116","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1021\/acs.jmedchem.0c01454","article-title":"HDAC-Bax multiple ligands enhance Bax-Dependent apoptosis in HeLa cells","volume":"63","author":"Liang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113453","article-title":"Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer","volume":"220","author":"Duan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib118","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1021\/acs.jmedchem.8b00393","article-title":"Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual inhibitors as a novel strategy for the combinational treatment of Leukemia and invasive fungal infections","volume":"61","author":"Huang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib119","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/0008-5472.CAN-17-1510","article-title":"Therapeutic targeting of oncogenic tyrosine posphatases","volume":"77","author":"Frankson","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","article-title":"Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition","volume":"24","author":"Wong","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib121","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.bbrc.2005.11.131","article-title":"Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death","volume":"339","author":"Ozaki","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib122","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbrc.2013.03.009","article-title":"Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models","volume":"433","author":"Sakamoto","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib123","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1021\/acs.jmedchem.2c00866","article-title":"Discovery of novel src homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib124","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib125","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrc3340","article-title":"The NAD metabolome--a key determinant of cancer cell biology","volume":"12","author":"Chiarugi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116579_bib126","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MOG.0b013e32801b3c8f","article-title":"The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt\/PBEF\/visfatin in mammals","volume":"23","author":"Revollo","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejmech.2024.116579_bib127","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.2174\/15680266113136660206","article-title":"NAD biosynthesis in humans--enzymes, metabolites and therapeutic aspects","volume":"13","author":"D\u00f6lle","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116579_bib128","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/259695a0","article-title":"Magnitude and significance of NAD turnover in human cell line D98\/AH2","volume":"259","author":"Rechsteiner","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116579_bib129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4161\/cbt.10.2.12581","article-title":"Nampt\/PBEF\/visfatin and cancer","volume":"10","author":"Bi","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2024.116579_bib130","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","article-title":"Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition","volume":"120","author":"Cea","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116579_bib131","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1242\/jcs.01540","article-title":"The AMP-activated protein kinase pathway--new players upstream and downstream","volume":"117","author":"Hardie","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2024.116579_bib132","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.bbrc.2012.11.010","article-title":"Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK","volume":"430","author":"Sinnett-Smith","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib133","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2010.06.052","article-title":"AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival","volume":"398","author":"Woodard","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116579_bib134","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116579_bib135","first-page":"334","article-title":"FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells, Biophys","volume":"458","author":"Schuster","year":"2015","journal-title":"Responsive Community"},{"key":"10.1016\/j.ejmech.2024.116579_bib136","volume":"12.27","author":"Jiang","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116579_bib137","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.devcel.2006.01.002","article-title":"An Shp2\/SFK\/Ras\/Erk signaling pathway controls trophoblast stem cell survival","volume":"10","author":"Yang","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2024.116579_bib138","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/eji.200636240","article-title":"The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual primary T lymphocytes","volume":"37","author":"Hoff","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2024.116579_bib139","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","article-title":"The role of Shp2 (PTPN11) in cancer","volume":"17","author":"Mohi","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejmech.2024.116579_bib140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","article-title":"The tyrosine phosphatase Shp2 in development and cancer","volume":"106","author":"Grossmann","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116579_bib141","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: a novel strategy for cancer therapy","volume":"67","author":"Liu","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2024.116579_bib142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256416","article-title":"Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1\/PD-L1 inhibitors","volume":"16","author":"Toral","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116579_bib143","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.apsb.2021.03.037","article-title":"Strategies to overcome drug resistance using SHP2 inhibitors","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116579_bib144","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2024.116579_bib145","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:25:54Z","timestamp":1720445154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424004598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":145,"alternative-id":["S0223523424004598"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116579","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116579"}}